http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
위전절제후 루프식도 공장문합술시 유입부루프결찰이 식도역류에 미치는 효과
김진복(Jin Pok Kim),이명철(Myung chul Lee),김경국(Kyung Koom Kim),김병식(Byung Sik Kim),김선희(Sun Whe Kim),이건욱(Kun Uk Lee),정준기(June Key Chung) 대한소화기학회 1988 대한소화기학회지 Vol.20 No.2
N/A Reflux esophagitis is a poor prognostic factor by worsening nutritional derangement of gastric cancer patients with total gastrectomy. To evaluate the effect of ligation of proximal loop for prevention of reflux esophagitis in gastric cancer patients with total gastrectomy and loop esophagojejunostomy and distal enteroenterostomy, we carried out the experiment on 9 patients with ligation of proximal loop as study group, 5 patients without ligation of proximal loop as control group. The extent of esophageal reflux was measured quantitatively after infusion of 99m Tc-pertechnetate into jejunum. When the abdomen was pressed with 0 mmHg 50 mmHg and 100 mmHg 30 min after infusion, esophageal reflux was significantly lower in study group than in control group, respectively. So, the technique of ligation of proximal loop in loop esophagojejunostomy and distal enteroenterostomy can be employed for prevention of esophageal reflux. But, we suggest that the role of loop as gastric reservoir, transit time of loop and the change of peristalsis after ligation of proximal loop be studied to evaluate the definitive effect of ligation of proximal loop for prevention of esophageal reflux.
전이성 유방암에 대한 Cyclophosphamide , Adriamycin , Methotrexate , 5 - FU ( CAMF ) 4 제 복합화학요법
김시영(Si Young Kim),김흥태(Heung Tae Kim),강윤구(Yoon Koo Kang),서철원(Cheol Won Suh),방영주(Yung Jue Bang),김노경(Noe Kyeong Kim),이건욱(Kun Uk Lee),최국진(Kuk Jin Choe),김수태(Soo Tae Kim) 대한내과학회 1988 대한내과학회지 Vol.34 No.6
N/A Between November, 1984 and January, 1987 32 patietns with metastatic breast cancer were treated with CAMF combination chemotherapy. Median age waa 45. Fourteen patients had prior chemotherapy and 2 patients had prior endocrine therapy. The menopausal status was as follows; 13 patients were postmenopausal, 19 premenopausal. The performance status was grade 0 to 1 (ECOG) in 13 patients, 2 in 12 and 3 in 7. Treatment was cyclophosphamide 750mg/m iv, day 1, adriamycin 30mg/㎟ iv, day 1; methotrexate 40mg/㎟ iv, day 8, and 5-FV 500 mg/㎟ iv, day 9. The treatment was recycled every 4 weeks until the progression of disease. Among 32 patients, 18 (56%) achived responses (1 CR and 17 RP), Median duration of response was 9 months. Median survival for all patients was 12 months. Toxicity was as follows; leukopenia 56 %, thrombocytopenia 15%, N/V 63%. No treatmentrelated death was observed during the treatment. It was concluded that CAMF combination chemotherapy is not superior to other cornbination chemotherapy regiments, and myelosuppression is a major dose-limiting toxicity.
위절제수술 후 역류성 식도염에 대한 Camostat Mesilate의 임상효과
이건영,한세환,이건욱 대한소화기학회 1998 대한소화기학회지 Vol.31 No.3
Background/Aims: Reflux esophagitis is one of common complications appeared after gastric surgeries. Bile reflux is considered as an important mechanism. Recently, reflux of pancreatic juice is also suggested as another important mechanism. Methods: In prospective randomised controlled studies on 80 patients with reflux symptoms after gastrectomy, the effects of treatment with camostat mesilate (Foipan^(R)), a trypsin inhibitor, were compared with those of treatment with other commonly prescribed drugs. Forty seven patients received camostat mesilate 300 mg/day for 8 weeks, and 33 patients were enrolled as other drug controls. Results: The rate of subjective symptom (heartburn) relief in the camostat mesilate treatment group was 87% after 8 weeks of treatment. Symptorns of regurgitation were relieved in 95% of patients, epigastric soreness in 85%, and dysphagia in 72%. In the control group, heartburn was relieved in 75% of patients after 8 weeks of treatment, regurgitation in 82%, epigastric soreness 75% dysphagia ln 80%. The symptoms of heartburn, regurgiation and epigastric soreness in the camostat treated group were significantly improved in comparison with the control group (p$lt;0.05). Moreover, the therapeutic effect was observed in early stage of treatment. In addition, there was no relationship between the severity of symptoms and the degree of endoscopic abnormality. There was no specific side effect in the camostat mesilate treatment group. Conclusions: These results suggest that camostat mesilate (Foipan^(R)) is effective in alleviating the symptoms of reflux esophagitis without significant side effect.